News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Aureon Laboratories Completes Initial Study with AstraZeneca PLC (AZN) Using Predictive Pathology to Stratify Patient Risk for Non-Small Cell Lung Cancer



9/6/2007 10:36:29 AM

YONKERS, N.Y.--(BUSINESS WIRE)--Aureon Laboratories, Inc. today announced the successful completion of a development project with AstraZeneca designed to identify patients with non-small-cell lung cancer that may benefit from treatment with IRESSA®.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES